

Appl. No. 09/888,358
Amendment dated May 24, 2005
Reply to Office Action of November 29, 2004

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

- 1-31. (canceled)
32. (currently amended) A method of detecting a variant CGI-69 polynucleotide in a sample, comprising detecting a polynucleotide encoding a polypeptide comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO:3, wherein the variant polynucleotide encodes an allelic variant of the polypeptide comprising SEQ ID NO:3.
- 33-34. (canceled)
35. (currently amended) The method of claim 32, wherein the ~~nucleic acid sequence~~ polynucleotide comprises SEQ ID NO:1.
- 36-37. (canceled)
38. (previously presented) The method of claim 32, wherein the detecting comprises amplifying the polynucleotide sequence with a primer.
39. (previously presented) The method of claim 32, wherein the detecting comprises hybridizing a probe to the polynucleotide.
40. (canceled)
41. (currently amended) The method of claim ~~40~~ 32, wherein the sample is from a mammal.
42. (previously presented) The method of claim 41, wherein the sample is from a human.

Appl. No. 09/888,358
Amendment dated May 24, 2005
Reply to Office Action of November 29, 2004

43. (currently amended) The method of claim 40 32, wherein the sample is blood, serum, cells, tissue, or combinations thereof.
44. (currently amended) A method of detecting a variant CGI-69 polynucleotide in a sample, comprising:
- (a) contacting the sample with a nucleic acid probe that hybridizes to a polynucleotide encoding a polypeptide comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO:3 under stringent conditions, wherein the variant polynucleotide encodes an allelic variant of the polypeptide comprising SEQ ID NO:3; and
 - (b) detecting a hybridization signal, wherein detection of the hybridization signal indicates a variant CGI-69 polynucleotide encoding an amino acid sequence having at least 98% sequence identity to SEQ ID NO:3.
45. (canceled)
46. (previously presented) The method of claim 44, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:3.
47. (canceled)
48. (previously presented) The method of claim 44, wherein the detecting comprises amplifying the polynucleotide sequence with a primer.
49. (previously presented) The method of claim 44, wherein the detecting comprises hybridizing a probe to the polynucleotide.
50. (canceled)
51. (previously presented) The method of claim 44, wherein the sample is from a mammal.

Appl. No. 09/888,358
Amendment dated May 24, 2005
Reply to Office Action of November 29, 2004

52. (previously presented) The method of claim 51, wherein the sample is from a human.
53. (previously presented) The method of claim 44, wherein the sample is blood, serum, cells, tissue, or combinations thereof.
54. (previously presented) The method of claim 32, wherein the polynucleotide comprises SEQ ID NO:1.
55. (previously presented) The method of claim 39, wherein the probe hybridizes to the polynucleotide or its complement under stringent conditions.
56. (withdrawn) The method of claim 55, wherein the probe comprises SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:14.
57. (currently amended) The method of claim 55, wherein the polynucleotide comprises a nucleic acid sequence corresponding to nucleotides ~~265~~263 to ~~288~~286 of SEQ ID NO:1.
58. (withdrawn) The method of claim 38, wherein the polynucleotide sequence amplified comprises a nucleic acid sequence of SEQ ID NO:1.
59. (withdrawn) The method of claim 39, wherein the probe hybridizes to a polynucleotide comprising a nucleic acid sequence of SEQ ID NO:1.
60. (withdrawn) The method of claim 55, wherein the polynucleotide comprises a nucleic acid sequence that encodes an amino acid sequence corresponding to amino acid residues 65 to 72 of SEQ ID NO:3.
61. (withdrawn) The method of claim 60, wherein the probe hybridizes at least to the nucleic acid sequence that encodes an amino acid sequence corresponding to amino acid residues 65 to 72 of SEQ ID NO:3.

Appl. No. 09/888,358
Amendment dated May 24, 2005
Reply to Office Action of November 29, 2004

62. (previously presented) The method of claim 32, wherein the oligonucleotide is a primer that hybridizes to the polynucleotide or its complement under stringent conditions.
63. (previously presented) The method of claim 32, wherein the polypeptide is localized in the mitochondrial membrane.
64. (withdrawn) The method of claim 44, wherein the polynucleotide comprises SEQ ID NO:1.
65. (previously presented) The method of claim 44, wherein the polynucleotide comprises a nucleic acid sequence corresponding to nucleotides 265 to 288 of SEQ ID NO:1.
66. (withdrawn) The method of claim 64, wherein the probe hybridizes to a polynucleotide encoding an amino acids sequence comprising SEQ ID NO:3.
67. (withdrawn) The method of claim 44, wherein the polynucleotide comprises a nucleic acid sequence that encodes an amino acid sequence corresponding to amino acid residues 65 to 72 of SEQ ID NO:3.
68. (withdrawn) The method of claim 66, wherein the nucleic acid probe hybridizes at least to the nucleic acid sequence that encodes an amino acid sequence corresponding to amino acid residues 65 to 72 of SEQ ID NO:3.
69. (withdrawn) The method of claim 44, wherein the nucleic acid probe comprises SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:13.
70. (withdrawn) The method of claim 44, wherein the polynucleotide sequence amplified encodes a polypeptide comprising an amino acid sequence of SEQ ID NO:3.

Appl. No. 09/888,358
Amendment dated May 24, 2005
Reply to Office Action of November 29, 2004

7169. (currently amended) The method of claim 44, wherein the polypeptide is localized in the mitochondrial membrane.

7270. (currently amended) The method of claim 43, wherein the tissue is adipose tissue.

7374. (currently amended) The method of claim 53, wherein the tissue is adipose tissue.